{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-087059","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.049410+00:00","generated_at":"2026-06-12T08:50:05.106907+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Replimune Q1 net loss $49.6M; CERPASS data delayed to early Q4; inks Incyte CSCC trial","bullets":["Net loss $49.6M in fiscal Q1 vs $42.3M a year ago; cash $539.1M provides runway into H2 2025.","CERPASS topline data (RP1+Libtayo in CSCC) expected early Q4 2023, delayed from Q3 due to slower independent review.","IGNYTE full cohort snapshot (N=141) in anti-PD1 failed melanoma on track for Q4 2023; BLA submission planned Q1/Q2 2024.","Clinical trial collaboration with Incyte to test RP1 + oral PD-L1 INCB99280 in neoadjuvant CSCC; trial to start early 2024, costs shared.","RP2/RP3 Phase 2 programs: third-line CRC trial initiated; HCC trial expected this quarter; Phase 1 completion in Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-087059","json":"https://secwatch.observer/filing/0001104659-23-087059.json","markdown":"https://secwatch.observer/filing/0001104659-23-087059.md","text":"https://secwatch.observer/filing/0001104659-23-087059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923087059/0001104659-23-087059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923087059/tm2317748d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:50:05.106907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ae75b7997e366de8e907847c8ce8617463542af","claim":"Replimune Group, Inc. reported financial results for fiscal first quarter ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, Replimune Group, Inc. (the “Company”) issued a news release announcing its financial results for the first quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465923087059/0001104659-23-087059-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal first quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}